These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
30. Advances in targeting HER2-positive breast cancer. Harbeck N Curr Opin Obstet Gynecol; 2018 Feb; 30(1):55-59. PubMed ID: 29194077 [TBL] [Abstract][Full Text] [Related]
31. Trastuzumab and vinorelbine in early stages of HER2-positive breast cancer. Ferrario C; Wong A; Gao T; Bouganim N; Aloyz R; Panasci LC J Chemother; 2011 Feb; 23(1):32-5. PubMed ID: 21482492 [TBL] [Abstract][Full Text] [Related]
32. Using TILs to Predict Therapeutic Effect of Chemotherapy (Pertuzumab, Trastuzumab, Docetaxel) on HER2-positive Breast Cancer. Kashiwagi S; Asano Y; Goto W; Takada K; Takahashi K; Hatano T; Takashima T; Tomita S; Motomura H; Ohsawa M; Hirakawa K; Ohira M Anticancer Res; 2017 Oct; 37(10):5623-5630. PubMed ID: 28982879 [TBL] [Abstract][Full Text] [Related]
33. Pertuzumab for the treatment of breast cancer: a safety review. Gao J; Swain SM Expert Opin Drug Saf; 2016 Jun; 15(6):853-63. PubMed ID: 26982349 [TBL] [Abstract][Full Text] [Related]
34. Implementation of trastuzumab in conjunction with adjuvant chemotherapy in the treatment of non-metastatic breast cancer in the Netherlands. de Munck L; Schaapveld M; Siesling S; Wesseling J; Voogd AC; Tjan-Heijnen VC; Otter R; Willemse PH Breast Cancer Res Treat; 2011 Aug; 129(1):229-33. PubMed ID: 21431871 [TBL] [Abstract][Full Text] [Related]
35. Trastuzumab emtansine in HER2-positive metastatic breast cancer: what is the best sequence? Ricci F; Le Tourneau C Chin Clin Oncol; 2018 Feb; 7(1):3. PubMed ID: 29156892 [No Abstract] [Full Text] [Related]
36. A phase II trial with trastuzumab and pertuzumab in patients with HER2-overexpressed locally advanced and metastatic breast cancer. Walshe JM; Denduluri N; Berman AW; Rosing DR; Swain SM Clin Breast Cancer; 2006 Feb; 6(6):535-9. PubMed ID: 16595039 [No Abstract] [Full Text] [Related]
37. HER2 intratumoral heterogeneity is independently associated with incomplete response to anti-HER2 neoadjuvant chemotherapy in HER2-positive breast carcinoma. Hou Y; Nitta H; Wei L; Banks PM; Portier B; Parwani AV; Li Z Breast Cancer Res Treat; 2017 Nov; 166(2):447-457. PubMed ID: 28799059 [TBL] [Abstract][Full Text] [Related]
38. Trastuzumab retreatment after relapse on adjuvant trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer: final results of the Retreatment after HErceptin Adjuvant trial. Láng I; Bell R; Feng FY; Lopez RI; Jassem J; Semiglazov V; Al-Sakaff N; Heinzmann D; Chang J Clin Oncol (R Coll Radiol); 2014 Feb; 26(2):81-9. PubMed ID: 24051172 [TBL] [Abstract][Full Text] [Related]
39. Estimated Life-Years Saved in Women with HER2-Positive Metastatic Breast Cancer Receiving First-Line Trastuzumab and Pertuzumab in the United States. Danese MD; Masaquel A; Santos E; Brammer M; Lee A; Lalla D Value Health; 2015 Sep; 18(6):876-83. PubMed ID: 26409616 [TBL] [Abstract][Full Text] [Related]
40. Is there a case for anti-HER2 therapy without chemotherapy in early breast cancer? Constantinidou A; Smith I Breast; 2011 Oct; 20 Suppl 3():S158-61. PubMed ID: 22015286 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]